Pharmaceutical companies are turning to drug delivery technologies to boost pipelines and compensate for patent losses. Currently marketed drugs are being repositioned through reformulation using novel drug delivery technologies and drug delivery approaches are being considered early in the development program of new chemical entities. Transdermal drug delivery is an attractive area of research due to the development of patch technologies that can be used to deliver drugs that are typically administered by injection in an effort to increase compliance and improve outcomes.

The 4P team is experienced in developing a broad range of transdermal drug delivery technologies. These range from conventional transdermal systems to novel transdermal technologies for use in the delivery of water soluble small molecules as well as peptides, proteins, vaccines and macromolecules that are typically delivered by needle injection. The company’s team also has experience with developing oral drug delivery technologies, medical devices, and diagnostics, skills which it leverages for the development of combination products.

4P specializes in accelerating products from concept to proof-of-concept, by moving quickly from the establishment of preclinical feasibility to the demonstration of proof-of-concept in humans. Once the product concept is demonstrated in humans, 4P leads the execution of the clinical/regulatory program as well as the tech transfer process, supports design for manufacturing, and manages its key contract manufacturing relationships during scale-up and commercialization.